A Look At BridgeBio Pharma (BBIO) Valuation After Phase 3 Wins And Attruby Commercial Momentum

Simply Wall St.

Yesterday

BridgeBio Pharma (BBIO) is back in focus after reporting Q4 and full year 2025 results, showing sharply higher revenue alongside continued net losses as investors weigh the impact of recent clinical ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2616507373"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616507373\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616507373?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-03 01:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616507373","market":"nz","top_or_hot":-1,"title":"A Look At BridgeBio Pharma (BBIO) Valuation After Phase 3 Wins And Attruby Commercial Momentum","media":"Simply Wall St.","content":"<div>\n<p>BridgeBio Pharma (BBIO) is back in focus after reporting Q4 and full year 2025 results, showing sharply higher revenue alongside continued net losses as investors weigh the impact of recent clinical ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-phase-3-wins\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At BridgeBio Pharma (BBIO) Valuation After Phase 3 Wins And Attruby Commercial Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At BridgeBio Pharma (BBIO) Valuation After Phase 3 Wins And Attruby Commercial Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-03 01:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-phase-3-wins><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BridgeBio Pharma (BBIO) is back in focus after reporting Q4 and full year 2025 results, showing sharply higher revenue alongside continued net losses as investors weigh the impact of recent clinical ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-phase-3-wins\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-phase-3-wins","article_id":"2616507373","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-phase-3-wins","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616507373","pubTimestamp":1772472275,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BridgeBio Pharma (BBIO) is back in focus after reporting Q4 and full year 2025 results, showing sharply higher revenue alongside continued net losses as investors weigh the impact of recent clinical and commercial progress.\nSee our latest analysis for BridgeBio Pharma.\nDespite the recent Q4 earnings and a series of positive Phase 3 readouts, BridgeBio Pharma’s short term share price returns have softened, with a 30 day share price return of 14.0% and year to date share price return of 15.0%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","BBIO":"BridgeBio Pharma, Inc."},"translate_title":"BridgeBio Pharma(BBIO)第三阶段获胜后的估值以及Attruby商业势头","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":1.5},"content_text":"BridgeBio Pharma (BBIO) is back in focus after reporting Q4 and full year 2025 results, showing sharply higher revenue alongside continued net losses as investors weigh the impact of recent clinical and commercial progress. See our latest analysis for BridgeBio Pharma. Despite the recent Q4 earnings and a series of positive Phase 3 readouts, BridgeBio Pharma’s short term share price returns have softened, with a 30 day share price return of 14.0% and year to date share price return of 15.0% declines, in contrast with a 1 year total shareholder return of 101.4% and a 3 year total shareholder return above 3x. This suggests longer term momentum has been strong even as near term sentiment cools. If this mix of clinical milestones and volatility has your attention, it could be a good moment to scan other genetic and biotech names through our screener of 28 healthcare AI stocks. With BridgeBio reporting US$502.1 million in annual revenue alongside a US$724.9 million net loss, and a share price that has pulled back after a very large 1 year total return, is the recent weakness opening a fresh entry point, or is the market already baking in future growth? AdvertisementMost Popular Narrative: 22.4% Undervalued BridgeBio Pharma’s most followed narrative, according to Vestra, pegs fair value at $85.68 per share versus the last close of $66.48, framing the current pullback as a potential discount to that thesis.  BridgeBio Pharma (BBIO) has successfully transitioned into a commercial-stage juggernaut, with shares trading at $68.14 as of February 22, 2026. The company is currently riding the momentum of its primary growth engine, Attruby (acoramidis), which reported preliminary 2025 revenues of $362.4 million. With over 6,600 unique prescriptions written by the end of last year, Attruby is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients, offering a highly competitive alternative to established treatments.  Read the complete narrative. If you want to see how Vestra gets from one drug’s early traction to a double digit upside case for the whole company, the key ingredients are aggressive revenue build out assumptions, maturing margins and a valuation multiple usually reserved for established rare disease players. Curious which levers matter most in that $85.68 fair value math, and how much weight is put on programs beyond Attruby? Result: Fair Value of $85.68 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are still clear pressure points. These include ongoing net losses of US$724.9 million and execution risk around turning pipeline assets into sustainable revenue drivers. Find out about the key risks to this BridgeBio Pharma narrative. Another View: High Sales Multiple Cuts the Other Way That 22.4% undervalued fair value hinges on long term cash flow assumptions, but the current P/S of 25.7x tells a different story. It sits above both US Biotechs at 12.5x and an estimated fair ratio of 22.4x. This points to valuation risk if growth or execution slip. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:BBIO P/S Ratio as at Mar 2026Next Steps Does this story feel optimistic or a bit stretched to you? Act while the facts are fresh and weigh both sides with 2 key rewards and 1 important warning sign. Ready to hunt for your next idea? If this update on BridgeBio has you thinking bigger, do not stop here. Put fresh names on your radar with a quick pass through these hand picked screens.  Target potential mispricings by scanning our list of 49 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them yet. Lock in income ideas by reviewing 13 dividend fortresses, a collection of higher yielding payers that could help anchor an income focused portfolio. Protect your downside by checking 76 resilient stocks with low risk scores, highlighting companies that score well on resilience so you are not only exposed to higher volatility names.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BridgeBio Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}